Pharmaceutical combination for the treatment of tissue...

Details Pharmaceutical combination for the treatment of tissue... Pharmaceutical combination for the treatment of tissue...

2008-04-22

2008-04-22

Spector, Lorraine (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C530S329000, C530S300000

Reexamination Certificate

active

10220750

ABSTRACT:
This invention relates to a medicine for humans, and particularly to a pharmaceutical combination comprising Epidermal Growth Factor (EGF) and Growth Hormone secretagogue hexapeptide (GHRP) for use in preventing tissue damage due to blood flow suppression by enhancing tissue repair following ischemic damage. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is also useful in promoting cellular survival when tissue or organs are exposed to prolonged ischemic periods. The combination is useful as a prophylactic agent in those subjects prone to multiple organ failure (MOF) such as burn victims, multiple trauma patients, hypoxic neonates, acute respiratory distress syndrome patients, and necrotizing enterocolitis patients.

REFERENCES:
patent: 5360790 (1994-11-01), Humes
patent: 6124263 (2000-09-01), Muccioli et al.
patent: 6191109 (2001-02-01), Besner et al.
patent: 6861409 (2005-03-01), Martinez et al.
patent: 0 357 240 (1990-03-01), None
patent: 1 002 802 (2000-05-01), None
patent: 1019970032600 (1997-07-01), None
patent: 100226985 (1999-07-01), None
patent: WO 98/22124 (1998-05-01), None
patent: WO 00/12047 (2000-03-01), None
patent: WO 01/85695 (2001-11-01), None
patent: WO 01/87322 (2001-11-01), None
Humes et al., Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in postischemic acute renal failure, J. Clin. Invest., 84:1757-1761, Dec. 1989.
Berti et al., Chapter 24: Hexarelin, a synthetic growth hormone secretagogue, exhibits protectant activity in experimental mycardial ischemia and reperfusion, Growth Hormone Secretagogues, E. Ghigo et al., Eds., (Elsevier: Amsterdam), pp. 301-314, 1999.
Weekers et al., Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of mycardial stunning in an isolated, blood-perfused rabbit heart model, Endocrinol., 141(11):3993-3999, 2000.
Ishikawa et al., Epidermal growth factor protects gastric mucosa against ischemia-reperfusion injury, J. Clin. Gastro., 17 (Sup. 1):S104-S110, 1993.
Sumi et al., Effect of human epidermal growth factor (hEGF) on splanchnic circulation in dogs, Life Sci., 47 :1115-1119, 1990.
Lee et al., Effects of epidermal growth factor (EGF) on ischemia-repertusion injury in rat liver, Chung-Ang J. Med., 25(4):195-205, Dec. 2000.
Bowers et al., Chapter 2: Xenobiotic growth hormone secretagogues: growth hormone releasing peptides, Growth Hormone Secretagogues, B.B. Bercu and R. Walker, Eds., (Springer: New York), pp. 9-28, 1996.
Muccioli et al., Growth hormone-releasing peptides and the cardiovascular system, Annales d'Endocrinologie, 61(1):27-31, Feg. 2000.
Locke et al., Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats, Life Sci., 56(16):1347-1352, 1995.
Hui et al., Effects of epidermal growth factor on gastric blood flow in rats: possible role in mucosal protection, Gastroenterology, 104:1605-1610, 1993.
BioTech Life Sciences Dictionary, (online) peptide, The Trustees of Indiana University, 1995-1998, accessed Apr. 23, 2007.
W. Ganong, Reviewof Medical Physiology, 17thEd., Appleton & Lange:Norwalk, CT, 1995, p. 268.
Halle et al., Importance of TNF-alpha and leptin in obesity and insulin resistance: a hypothesis on the impact of physical exercise, Exercise Immunology Review, 4:77-94, 1998.
Svensson et al., The GH secretagogues ipamorelin and GH-releasing peptide-6 increased bone mineral content in adult female rats, J. Endocrinology, 165:569-577, 2000.
Iannoli et al., Epidermal growth factor and human growth hormone accelerate adaptation after massive enterectomy in an additve nutrient-dependent, and site-specific fashion, Surgery, 122:721-729, 1997.
Thompson, J.S., Epidermal growth factor and the short bowel syndrome, J. Parenteral and Enteral Nutrition, 23(5):S113-S116, Sep./Oct. 1999.
Deghenghi et al., GH-releaseing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats, Life Sci. 54(18):1321-1328, 1994.
Bowers et al., On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone, Endocrinol. 114(5):1537-1545.
Lecour et al., Identification of a novel role for sphingolipid signaling in TNF-alpha and ischemic preconditioning mediated cardioprotection, J. Mol. Cell. Cardiol. 34:509-518, 2002.
Martin et al., Timing, route, and dose of administration of heparin-binding epidermal growth factor-like growth factor in protection against intestinal ischemia-reperfusion injury, J. Ped. Surg. 40:1741-1747, 2005.

Affiliated with

Also associated with

Rating

Pharmaceutical combination for the treatment of tissue... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical combination for the treatment of tissue..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical combination for the treatment of tissue... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3908606